Vertex Pharmaceuticals Inc (VRTX)

161.97
4.14 2.49
NASDAQ : Health Care
Prev Close 166.11
Open 166.94
Day Low/High 161.72 / 167.85
52 Wk Low/High 75.90 / 143.45
Volume 2.42M
Avg Volume 2.07M
Exchange NASDAQ
Shares Outstanding 249.07M
Market Cap 40.64B
EPS -0.50
P/E Ratio 233.10
Div & Yield N.A. (N.A)

Latest News

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.

Closing Bell: Vertex Pharmaceuticals Up on String of Upgrades; Records for Wall Street

Closing Bell: Vertex Pharmaceuticals Up on String of Upgrades; Records for Wall Street

The Nasdaq and S&P 500 ended at records for the second day in a row.

S&P 500 and Nasdaq Hover at Session Highs, Apple on Pace for 9-Day Win Streak

S&P 500 and Nasdaq Hover at Session Highs, Apple on Pace for 9-Day Win Streak

S&P 500 and Nasdaq at record highs.

Vertex Growth Expected to Continue with Life-Changing Cystic Fibrosis Treatment

Vertex Growth Expected to Continue with Life-Changing Cystic Fibrosis Treatment

Remarkable data was released from Vertex's triple regiment combination trials.

Biotech Movers: Vertex Continues to Move on Data for CF Regimen

Biotech Movers: Vertex Continues to Move on Data for CF Regimen

Vertex Pharmaceuticals, FibroGen and Inovio Pharmaceuticals were among the biotech stock movers in premarket trading trading on July 19.

Vertex Pharmaceuticals Stock Surging on Positive Trial Data

Vertex Pharmaceuticals Stock Surging on Positive Trial Data

Cystic fibrosis is an inherited disorder that causes damage to the lungs, digestive system, and other organs of the body.

Vertex Announces Positive Phase 1 & Phase 2 Data From Three Different Triple Combination Regimens In People With Cystic Fibrosis Who Have One F508del Mutation And One Minimal Function Mutation (F508del/Min)

Vertex Announces Positive Phase 1 & Phase 2 Data From Three Different Triple Combination Regimens In People With Cystic Fibrosis Who Have One F508del Mutation And One Minimal Function Mutation (F508del/Min)

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive data from Phase 1 and Phase 2 studies of three different triple combination regimens in people with cystic fibrosis (CF) who have one F508del...

Vertex Awards Two First-Generation College Students Full Scholarships To The University Of Massachusetts

Vertex Awards Two First-Generation College Students Full Scholarships To The University Of Massachusetts

Vertex, Boston Public Schools (BPS) and the University of Massachusetts today announced the recipients of the annual Vertex Science Leaders Scholarship, a four-year, full-ride scholarship to pursue an education in...

These Are the Best Growth Stocks Right Now in Biotech

These Are the Best Growth Stocks Right Now in Biotech

Top names.

Vertex To Announce Second Quarter 2017 Financial Results On July 26

Vertex To Announce Second Quarter 2017 Financial Results On July 26

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2017 financial results on Wednesday, July 26, 2017 after the financial markets close.

Vertex Announces Reimbursement Agreement In Italy For ORKAMBI® (Lumacaftor/Ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation

Vertex Announces Reimbursement Agreement In Italy For ORKAMBI® (Lumacaftor/Ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco, or AIFA) has agreed to reimburse ORKAMBI ® (lumacaftor/ivacaftor), the first...

3 Red-Hot Biotech Stocks That Could Get Even Hotter

3 Red-Hot Biotech Stocks That Could Get Even Hotter

An analyst weighs in.

Here's a Great Place to Find Dividends If You Are Terrified About a Stock Market Correction

Here's a Great Place to Find Dividends If You Are Terrified About a Stock Market Correction

Investors, antsy about increased volatility in the markets, might look to high dividend yielding REITs to ride out the uncertainty.

How President Trump Has Sent Biotech Stocks Soaring

How President Trump Has Sent Biotech Stocks Soaring

The iShares NASDAQ Biotechnology Index ended the five days ended Friday, June 23 up 26% to close at $370.74.

You Will Live to 110 or 120 Years Old, So Don't Make This One Killer Mistake About Your Retirement

You Will Live to 110 or 120 Years Old, So Don't Make This One Killer Mistake About Your Retirement

You're thinking about your retirement all wrong.

Vertex To Present At The Goldman Sachs Healthcare Conference On June 13

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference on Tuesday, June 13, 2017 at 12:20 p.

Vertex Announces Nine Presentations Of Data On ORKAMBI® (lumacaftor/ivacaftor) And KALYDECO® (ivacaftor) At The European Cystic Fibrosis Society (ECFS) Conference

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced nine presentations of data on ORKAMBI ® (lumacaftor/ivacaftor) and KALYDECO ® (ivacaftor) at the 40 th European Cystic Fibrosis Society...

Vertex Names Dr. Alan Garber, Provost Of Harvard University, To Its Board Of Directors

Shareholders of Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today elected Alan M.

Analysts' Actions -- ADP, Charter, Deere, Coty, Ulta Beauty and More

Analysts' Actions -- ADP, Charter, Deere, Coty, Ulta Beauty and More

Here are Friday's top research calls, including a downgrade for Automatic Data Processing, new coverage of Charter and Coty, and upgrades for Deere and Ulta Beauty.

Vertex Announces Long-Term Reimbursement Agreement With The Republic Of Ireland For ORKAMBI® (lumacaftor/ivacaftor), KALYDECO® (ivacaftor) And Future Cystic Fibrosis Medicines

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced it has reached an agreement with the Health Service Executive (HSE) in the Republic of Ireland to fund ORKAMBI ® (lumacaftor/ivacaftor) for all...

Vertex Undergoes FTC Scrubbing for Deal on CF Treatment

Vertex Undergoes FTC Scrubbing for Deal on CF Treatment

The key issue for the FTC is whether the deal kills competition between Concert's treatment and Vertex's Kalydeco.

Vertex Awards 40 Scholarships Totaling $200,000 To People Living With Cystic Fibrosis And Their Immediate Family Members

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first recipients of the company's All in for CF Scholarship program.

Vertex To Present At The UBS Healthcare Conference On May 23

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the UBS Healthcare Conference on Tuesday, May 23, 2017 at 11:00 a.

FDA Approves KALYDECO® (ivacaftor) For More Than 900 People Ages 2 And Older With Cystic Fibrosis Who Have Certain Residual Function Mutations

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.

Cramer: These Sectors Look Bullish (Part III)

Cramer: These Sectors Look Bullish (Part III)

From Abbott Labs to Wynn, these names rate checking out.

Cramer: There Are Powerful Themes in Several Bull Markets

Cramer: There Are Powerful Themes in Several Bull Markets

It's a wonder to me how split this market really is.

Vertex Grants $1 Million To 15 Non-profit Organizations To Advance Initiatives For People Living With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the grant recipients for its 2017 Cystic Fibrosis (CF) Circle of Care program, an initiative that funds innovative, patient-centric programs for the CF...

Analysts' Actions -- Adobe, AMD, Chegg, Okta and More

Analysts' Actions -- Adobe, AMD, Chegg, Okta and More

Here are Tuesday's top research calls, including new coverage of Adobe and Okta, a downgrade for Advanced Micro Devices and an upgrade for Chegg.